Radiolabeling and PET–MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer
Cancer Nanotechnology July 11, 2021 Mariane Le Fur, Alana Ross, Pamela Pantazopoulos et al.
A therapeutic agent designed to target microRNA-10b, which controls metastatic tumor cell survival, was radiolabeled with copper-64 and tested in mice to see whether it would accumulate in human-like metastases. The agent, MN-anti-miR10b, showed comparable distribution whether given at a therapeutic dose or a tracer-level microdose. Using PET–MRI, uptake was observed in metastatic lymph nodes, lungs, and bone, with significantly higher signals than in the same organs without metastases. The findings indicate that a microdose injection can accurately reflect the therapeutic's biodistribution, supporting future clinical testing in cancer patients.